A Real‐World Phase <scp>IV</scp> Superiority Trial and Cost‐Effectiveness Analysis of the Addition of Low‐Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer
A significant improvement in survival, tolerability, and reasonable cost-effectiveness was observed with low-dose immunotherapy when added to oral metronomic chemotherapy compared to conventional chemotherapy regimens.
Authors
- Rushabh Kothari (ORCID: https://orcid.org/0000-0002-3910-5649)
- Manthan Merja
- Yashasvi Chauhan (ORCID: https://orcid.org/0000-0003-3508-6679)
- Avinash Khadela (ORCID: https://orcid.org/0000-0001-9914-8539)
- Roma Parikh (ORCID: https://orcid.org/0000-0001-5425-4901)
- Vraj B. Shah (ORCID: https://orcid.org/0009-0003-8080-5086)
- Jaydeep Vaghela
Institutions
- Gujarat University (IN)
- Sterling Hospitals (IN)
- Gujarat Cancer & Research Institute (IN)
- HCG Cancer Centre (IN)
- B.J. Medical College (IN)
Publication Details
- Journal
- Head & Neck
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1002/hed.70077
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05